Ebola vaccine memory under the microscope: how long does it last?
NCT ID NCT06100913
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study gives 30 healthy adults a single dose of the approved Ebola vaccine (Ervebo) and tracks their immune responses over time using blood, lymph node, and bone marrow samples. The goal is to understand how long the body 'remembers' the vaccine, which could guide future booster schedules. It is not testing the vaccine's effectiveness against Ebola, but rather the durability of immune memory.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Ebola vaccine (Ervebo)
- What this could lead to
- If successful, this could help determine how often booster shots are needed to maintain protection against Ebola.
- What could go wrong
- This is a small, early-phase study focused on immune response, not on preventing disease. Results may not predict real-world protection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
30 people
The number who actually took part.
- Started
-
Aug 2024
- Expected to finish
-
Aug 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Signed informed consent for study. * For women of childbearing potential: willing to engage in effective methods of contraception starting at least 28 days prior to vaccination and during the study. * Willing to minimize blood and body fluid exposure to others (encourage abstinence, and hand hygiene; discourage contact with blood, vomit, feces without personal protective equipment (PPE) for at least 14 days following vaccine administration. * Willing to forgo blood donation 30 days prior to and for the duration of study participation. Exclusion Criteria: * At risk of travel-related or occupational exposure to Ebola virus such as through laboratory, clinical contact, field work, or in the judgment of the investigator. * Received any Ebola vaccines or have history of Ebola Virus Disease (EVD). * Current or previous diagnosis of immunocompromising condition such as human immunodeficiency virus or other immunosuppressive condition by receiving systemic immunosuppressants or immune-modifying drugs for \>14 days in total within 6 months prior to screening (for corticosteroids: ≥ 10mg/day of prednisone or equivalent) or anticipates the need for immunosuppressive treatment at any time during participation in the study. * Pregnant and/or breastfeeding (must have urine pregnancy test on the day of vaccination and during screening visit) * Known allergy to any component of the rVSV∆G-ZEBOV-GP vaccine products (VSV, albumin, tris, rice protein). * History of severe local or systemic reactions to any vaccination. * Received investigational drug within 5 half-lives or 28 days, whichever is longer, prior to study vaccination. * Received or intends to receive vaccines within 28 days prior to or following study vaccination. * Received immunoglobulins and/or any blood products within 120 days prior to study vaccination. * Clinical evidence of systemic infection or other acute intercurrent illness (e.g. oral temp \>38°C or \> 100.4°F) less than 72 hours prior to study vaccination. * Currently has symptomatic, acute, or unstable chronic disease requiring medical or surgical care, to include significant change in therapy or hospitalization, at the discretion of the investigator. * History of excessive alcohol consumption, drug abuse, psychiatric conditions, social conditions, or occupational conditions that in the opinion of the investigator would preclude compliance with the study. * Any condition that would limit the ability of the participant to meet protocol requirements or would place the participant at unreasonable risk in the opinion of the investigator.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Ebola virus disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Hope Clinic of the Emory Vaccine Center
Decatur, Georgia, 30030, United States
-
Washington University in St. Louis
St Louis, Missouri, 63130, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ebola vaccine trial aims to shield frontline workers in congo
- Ebola vaccine in a nasal spray? early trial halted
- Could a vaccine and antibody combo stop ebola after exposure?
- UK volunteers test new ebola vaccine combo in Early-Stage trial
- Ebola antibody cocktail made available in emergency outbreak
- Hope in a pill? ebola drug favipiravir tested in guinea